Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

BACKGROUND: The IMpassion130 trial demonstrated that adding atezolizumab to nanoparticle albumin-bound (nab)-paclitaxel improved the survival of patients with untreated, advanced, programmed death ligand 1 (PDL1)-positive triple-negative breast cancer (TNBC). In view of the high cost of immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Phua, Lee Cheng, Lee, Soo Chin, Ng, Kwong, Abdul Aziz, Mohamed Ismail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315527/
https://www.ncbi.nlm.nih.gov/pubmed/32580722
http://dx.doi.org/10.1186/s12913-020-05445-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315527/
https://www.ncbi.nlm.nih.gov/pubmed/32580722
http://dx.doi.org/10.1186/s12913-020-05445-6

Ejemplares similares